Oral Prebiotic Polysaccharide Hydrogels Sustaining Colon Antibody Release Alleviate Inflammatory Bowel Disease
Advanced Science · 2026-09 · 13 (54)
DOI: 10.1002/advs.76425 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, online erschienen am 06.07.2026. Verfasst von Xinyi Dong und 4 weiteren Autor:innen. Beteiligte Einrichtung: Biomedical Polymers Laboratory, College of Chemistry, Chemical Engineering and Materials Science, Soochow University, Suzhou, China. Hauptthemen laut MEDLINE: Hydrogels, Inflammatory Bowel Diseases, Prebiotics, Colon. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: China Postdoctoral Science Foundation, Natural Science Foundation of Jiangsu Province.
Abstract (Originalsprache)
Inflammatory bowel disease (IBD) is a chronic systemic immune disorder with unclear pathogenesis that involves complex interplay between inflammation, gut microbiota, and immune dysregulation. The advance of antibodies targeting tumor necrosis factor‐alpha and interleukin‐12/23, e.g., infliximab (IFX) and ustekinumab (UTK), has greatly improved the clinical treatments. The current intravenous dosing scheme, however, yields partial responses with potentially severe systemic side effects. Here, we report that oral prebiotic polysaccharide hydrogels based on inulin and alginate‐dopamine conjugate (predaGel) mediating efficient and sustained colon antibody delivery and reactive oxygen species (ROS) scavenging effectively alleviate IBD. predaGel with pH and enzyme dual responsiveness is stable in the stomach, adhesive to the intestine, and slowly degrading in the colon, resulting in site‐specific and controlled release of IFX. The mucosal retention, ROS scavenging, and gut microbiota remodeling properties endowed by dopamine and inulin in predaGel not only prevent diarrhea and suppress oxidative stress but also prolong drug function and restore immune homeostasis. Intriguingly, oral administration of IFX and/or UTK‐encapsulated predaGel cures IBD and restores colon function, offering an effective oral alternative to IFX injection. This oral prebiotic hydrogel strategy, with simplicity and multi‐functions, presents a potentially safer and better biologic therapy for IBD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Biomedical Polymers Laboratory, College of Chemistry, Chemical Engineering and Materials Science, Soochow University, Suzhou, China.
- College of Pharmaceutical Sciences, Soochow University, Suzhou, China.
Förderung
- China Postdoctoral Science Foundation
- Natural Science Foundation of Jiangsu Province
Zitieren
APA
Dong, X., He, H., Cao, L., Meng, F., & Zhong, Z. (2026). Oral Prebiotic Polysaccharide Hydrogels Sustaining Colon Antibody Release Alleviate Inflammatory Bowel Disease. Advanced Science, 13(54). https://doi.org/10.1002/advs.76425
Vancouver
Dong X, He H, Cao L, Meng F, Zhong Z. Oral Prebiotic Polysaccharide Hydrogels Sustaining Colon Antibody Release Alleviate Inflammatory Bowel Disease. Advanced Science. 2026;13(54). doi:10.1002/advs.76425
BibTeX
@article{Dong2026,
author = {Dong, Xinyi and He, Huan and Cao, Li and Meng, Fenghua and Zhong, Zhiyuan},
title = {Oral Prebiotic Polysaccharide Hydrogels Sustaining Colon Antibody Release Alleviate Inflammatory Bowel Disease},
journal = {Advanced Science},
year = {2026},
volume = {13},
number = {54},
doi = {10.1002/advs.76425}
}
EUVIMED